Merck delivers vital data on evobrutinib
Treatment is an BTK inhibitor and has demonstrated a sound safety and tolerability profile
Read More
Tag: evobrutinib
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
